Literature DB >> 16212072

Current perspective. Diabetic vascular disease: from endothelial dysfunction to atherosclerosis.

Riccardo Candido1, Michela Zanetti.   

Abstract

Cardiovascular complications are the leading cause of death in diabetes. Over the past decade a number of studies have addressed the underlying mechanisms. Derangements of endothelial function, also referred to as endothelial dysfunction, have emerged to be the crucial early step in the development of atherosclerosis and are also involved in plaque progression and clinical emergence. Endothelial dysfunction is a condition of impaired endothelium-dependent vasodilation and most important of "endothelial activation", characterized by a proinflammatory, proliferative, and procoagulatory milieu that promotes initiation and complications of atherogenesis. A synergistic cross-talk among the conventional cardiovascular risk factors associated with diabetes contributes to disruption of endothelial integrity and accelerated atherosclerosis. This review will focus on the multifactorial nature of endothelial dysfunction in diabetes, the relationship between endothelial dysfunction, conventional cardiovascular risk factors and atherosclerosis, and the therapeutic options to improve endothelial function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16212072

Source DB:  PubMed          Journal:  Ital Heart J        ISSN: 1129-471X


  2 in total

1.  CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility.

Authors:  Hisham A E Awad; Azza A G Tantawy; Rania A El-Farrash; Eman A Ismail; Noha M Youssif
Journal:  Blood Transfus       Date:  2013-11-15       Impact factor: 3.443

2.  Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.

Authors:  Ashish Kumar Sharma; Sachin Kumar Raikwar; Muneem Kumar Kurmi; Bharthu Parthsarthi Srinivasan
Journal:  Inflammopharmacology       Date:  2012-10-31       Impact factor: 4.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.